Cargando…

Biomarkers for Treatment Response in Rheumatoid Arthritis: Where are they?

Detalles Bibliográficos
Autores principales:	Zhao, Sizheng Steven, Moots, Robert J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sciendo 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524768/ https://www.ncbi.nlm.nih.gov/pubmed/36465079 http://dx.doi.org/10.2478/rir-2020-0008

Ejemplares similares

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
por: Zhao, Sizheng, et al.
Publicado: (2018)

Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
por: Chadwick, Laura, et al.
Publicado: (2018)

Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol
por: Barnes, Theresa, et al.
Publicado: (2007)

Biomarkers in Rheumatoid Arthritis
por: Goëb, Vincent, et al.
Publicado: (2014)

Large joints are progressively involved in rheumatoid arthritis irrespective of rheumatoid factor status—results from the early rheumatoid arthritis study
por: Zhao, Sizheng Steven, et al.
Publicado: (2021)

Depression and anxiety symptoms at TNF inhibitor initiation are associated with impaired treatment response in axial spondyloarthritis
por: Zhao, Sizheng Steven, et al.
Publicado: (2021)

Arthritis: where are the T cells?
por: Kamradt, Thomas, et al.
Publicado: (2010)

Markers of Treatment Response to Methotrexate in Rheumatoid Arthritis: Where Do We Stand?
por: Halilova, Karina I., et al.
Publicado: (2012)

Adipokines and risk of rheumatoid arthritis: A two-sample multivariable Mendelian randomisation study
por: Vasileiadis, Georgios K., et al.
Publicado: (2023)

Comorbidity and response to TNF inhibitors in axial spondyloarthritis: longitudinal analysis of the BSRBR-AS
por: Zhao, Sizheng Steven, et al.
Publicado: (2020)

Rheumatoid Arthritis
por: Melchiorre, Daniela, et al.
Publicado: (2013)

Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis
por: Zhao, Sizheng Steven, et al.
Publicado: (2022)

Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
por: Benson, Rosalind, et al.
Publicado: (2020)

Vasculogenesis in rheumatoid arthritis
por: Szekanecz, Zoltán, et al.
Publicado: (2010)

Rheumatoid Arthritis in Minorities
por: Anaya, Juan-Manuel, et al.
Publicado: (2013)

Atherosclerosis in Rheumatoid Arthritis
por: González-Gay, Miguel A., et al.
Publicado: (2012)

Fatigue in rheumatoid arthritis
por: Choy, Ernest H, et al.
Publicado: (2019)

Rituximab treatment in rheumatoid arthritis: how does it work?
por: Boumans, Maria JH, et al.
Publicado: (2009)

The impact of education inequality on rheumatoid arthritis risk is mediated by smoking and body mass index: Mendelian randomization study
por: Zhao, Sizheng Steven, et al.
Publicado: (2021)

Rheumatoid Arthritis and Vascular Failure - Rheumatoid Arthritis Is a Risk Factor for Cardiovascular Disease-
por: Oyama, Jun-ichi, et al.
Publicado: (2019)

Biomarkers for Alzheimer’s Disease: Where Do We Stand and Where Are We Going?
por: Villa, Chiara
Publicado: (2020)

Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2023)

Rheumatoid Arthritis Synovial Fluid Neutrophils Drive Inflammation Through Production of Chemokines, Reactive Oxygen Species, and Neutrophil Extracellular Traps
por: Wright, Helen L., et al.
Publicado: (2021)

Nutrition and Diet in Rheumatoid Arthritis
por: Cutolo, Maurizio, et al.
Publicado: (2022)

Solid Cancers and Rheumatoid Arthritis
por: Kalliolias, George D., et al.
Publicado: (2023)

Genetically Determined Circulating Levels of Cytokines and the Risk of Rheumatoid Arthritis
por: Qian, Yu, et al.
Publicado: (2022)

Biomarkers in Rheumatoid Arthritis
por: Shapiro, Samantha C
Publicado: (2021)

Effective rheumatoid arthritis treatment requires comprehensive management strategies
por: Boomershine, Chad S
Publicado: (2009)

Challenges and opportunities for diagnosis and treatment of rheumatoid arthritis in Latin America
por: Pineda, Carlos, et al.
Publicado: (2015)

Increasing smoking intensity is associated with increased disease activity in axial spondyloarthritis
por: Zhao, Sizheng, et al.
Publicado: (2016)

Where to Stand with Stromal Cells and Chronic Synovitis in Rheumatoid Arthritis?
por: Brondello, Jean-Marc, et al.
Publicado: (2019)

Functional genomics and rheumatoid arthritis: where have we been and where should we go?
por: Jarvis, James N, et al.
Publicado: (2010)

Biomarkers for Psychiatric Disorders: Where Are We Standing?
por: Martins-de-Souza, Daniel
Publicado: (2013)

Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis
por: Zhao, Sizheng Steven, et al.
Publicado: (2020)

Androgens in rheumatoid arthritis: when are they effectors?
por: Cutolo, Maurizio
Publicado: (2009)

Understanding IFNλ in rheumatoid arthritis
por: de Groen, Rik A, et al.
Publicado: (2014)

Humoral Response to Microbial Biomarkers in Rheumatoid Arthritis Patients
por: Jasemi, Seyedesomaye, et al.
Publicado: (2021)

Association between comorbidities and disease activity in axial spondyloarthritis: results from the BSRBR-AS
por: Zhao, Sizheng Steven, et al.
Publicado: (2020)

Where Is the Responsibility?
Publicado: (1886)

Biomarkers for cancer cachexia: where do we stand?
por: Palus, Sandra, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ditjn7bmb2f94a54g76brmf74j